Business Context and Reporting Period
This Form 8-K Current Report was filed by Oragenics, Inc. (also referred to as ONI Biopharma Inc.) on December 19, 2008. The filing primarily addresses regulatory disclosure under Regulation FD regarding an audio update on the launch of the product EvoraPlus™ and the company's listing on the Alternext Paris exchange. Additionally, the report announces a change in the company's trading symbol.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events and disclosures rather than financial performance data.
Material Changes
- Trading Symbol Change: The company's trading symbol has changed from "ONI" to "ORNI".
- Product Launch: The company launched EvoraPlus™.
- Market Listing: The company is listed on the Alternext Paris exchange and is eligible for trading on the OTCBB.
Guidance, Outlook, and Risks
Management provided an audio update regarding the product launch and listing status, with a transcript attached as Exhibit 99.1. The filing explicitly states that the information is summary in nature and should be considered in the context of other SEC filings. The company undertakes no duty or obligation to publicly update or revise the information contained in this report, though it may do so at management's discretion. No specific financial guidance or risk factors were detailed within the text of this specific 8-K.
Investor Verification Checklist
- Verify the new ticker symbol "ORNI" on trading platforms.
- Review the attached transcript (Exhibit 99.1) for details on the EvoraPlus™ launch and Alternext Paris listing.
- Check the OTCBB eligibility status as mentioned in the report.
- Consult subsequent SEC filings for financial data, as this report does not contain quantitative financial metrics.